



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61P 19/08 ^(2006.01) **A61P 25/28** ^(2006.01)
A61P 31/00 ^(2006.01) **A61P 33/00** ^(2006.01)
A61P 35/00 ^(2006.01) **A61P 37/00** ^(2006.01)
A61P 37/06 ^(2006.01) **C07D 303/36** ^(2006.01)
C07D 301/03 ^(2006.01) **C07K 5/087** ^(2006.01)

(48) Corrigendum issued on:
17.10.2018 Bulletin 2018/42

(45) Date of publication and mention
of the grant of the patent:
18.07.2018 Bulletin 2018/29

(21) Application number: **12197779.7**

(22) Date of filing: **03.10.2008**

(54) **Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides**

Kristalline Peptideoxyketone als Proteaseinhibitoren und Synthese von Aminosäureketoepoxiden
Inhibiteurs de protéase époxy-cétone peptidique cristalline, et synthèse de céto-époxydes d'acides aminés

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**

(30) Priority: **04.10.2007 US 997613 P**
20.12.2007 US 8987 P

(43) Date of publication of application:
10.07.2013 Bulletin 2013/28

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
08834964.2 / 2 207 791

(73) Proprietor: **Onyx Therapeutics, Inc.**
Thousand Oaks, CA 91320-1799 (US)

(72) Inventors:
• **Phiasivongsa, Pasit**
Brentwood, CA 94513 (US)
• **Sehl, Louis C.**
Redwood City, CA 94062 (US)
• **Fuller, William Dean**
San Diego, CA 92117 (US)

• **Laidig, Guy J.**
Menlo Park, CA 94025 (US)

(74) Representative: **Carlisle, Julie et al**
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE (GB)

(56) References cited:
WO-A1-2006/017842 US-A1- 2005 245 435

• **SIN N ET AL: "Total synthesis of the potent
proteasome inhibitor epoxomicin: a useful tool
for understanding proteasome biology",
BIOORGANIC & MEDICINAL CHEMISTRY
LETTERS, PERGAMON, AMSTERDAM, NL, vol. 9,
no. 15, 2 August 1999 (1999-08-02) , pages
2283-2288, XP004174176, ISSN: 0960-894X, DOI:
10.1016/S0960-894X(99)00376-5**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- | | |
|--|--|
| <ul style="list-style-type: none">• VERDOES MARTIJN ET AL: "Mixing of peptides and electrophilic traps gives rise to potent, broad-spectrum proteasome inhibitors", ORGANIC & BIOMOLECULAR CHEMISTRY, ROYAL SOCIETY OF CHEMISTRY, GB, vol. 5, no. 9, 7 May 2007 (2007-05-07), pages 1416-1426, XP009106919, ISSN: 1477-0520, DOI: 10.1039/B702268A | <ul style="list-style-type: none">• HO ET AL: "LMP2-Specific Inhibitors: Chemical Genetic Tools for Proteasome Biology", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 14, no. 4, 27 April 2007 (2007-04-27) , pages 419-430, XP022047028, ISSN: 1074-5521, DOI: 10.1016/J.CHEMBIOL.2007.03.008 |
|--|--|